| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000026760 |
| Receipt No. | R000030723 |
| Official scientific title of the study | A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients withsmall vessel disease |
| Date of disclosure of the study information | 2017/03/29 |
| Last modified on | 2017/03/29 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients withsmall vessel disease | |
| Title of the study (Brief title) | A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients withsmall vessel disease | |
| Region |
|
|
| Condition | ||
| Condition | Coronary artery disease | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To compare the safety and efficacy of paclitaxel-coated balloon with plain balloon for coronary artery small vessel disease |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Target vessel failure |
| Key secondary outcomes | Procedural success
Clinical success MACE TLR Restenosis Late lumen loss |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Single blind -participants are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Paclitaxel-coated balloon | |
| Interventions/Control_2 | Plain balloon | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Stable or unstable angina or asymptomatic myocardial ischemia
Patients who met the treatment criteria for PCI RVD 2.0mm or larger and <2.75 mm with lesions length <22mm Stenosis of the native coronary artery >50% and <100% |
|||
| Key exclusion criteria | Acute myocardial infarction within 72 hour after onset; acute cardiac failure; pregnancy or lactation; renal dysfunction (serum creatinine >1.5 mg/dl); low left ventricular function (left ventricular ejection fraction <30%)
Contraindications or known intolerance to antiplatelet agents, paclitaxel, or contrast agents Lesions in the left main branch; patients meeting the criteria for coronary artery bypass graft (CABG); lesions 2mm or shorter from a bifurcation; multiple lesions in a single branch; patients with highly calcified lesions that were difficult to dilate with a balloon; high-grade bend lesions 90% or more; Previously undergone placement of a paclitaxel-eluting stent or had undergone DES placement within the preceding 24 weeks |
|||
| Target sample size | 135 | |||
| Research contact person | |
| Name of lead principal investigator | Atsushi Funatsu |
| Organization | Kyoto Katsura hospital |
| Division name | Cardiovascular center |
| Address | Yamadahirao-cho, Nishikyo-ku, Kyoto city |
| TEL | 075-382-3185 |
| kcvc.funatsu@katsura.com | |
| Public contact | |
| Name of contact person | Noriko Fujita |
| Organization | Kyoto Katsura hospital |
| Division name | Clinical reserch center |
| Address | Yamadahirao-cho, Nishikyo-ku, Kyoto city |
| TEL | 075-391-5811 |
| Homepage URL | |
| noriko.fujita@katsura.com | |
| Sponsor | |
| Institute | Nipro Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Nipro Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030723 |